XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Equity (Tables)
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of Stock by Class
Preferred stock authorized, issued and outstanding was as follows at both March 31, 2023 and December 31, 2022:
SeriesShares
Authorized
Shares Issued and
Outstanding
Floating Rate Non-Cumulative Preferred Stock, Series A27,600,000 24,000,000 
5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D500,000 500,000 
5.625% Non-Cumulative Preferred Stock, Series E32,200 32,200 
4.75% Non-Cumulative Preferred Stock, Series F40,000 40,000 
3.85% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G1,000,000 1,000,000 
Series A Junior Participating Preferred Stock10,000,000 — 
Not designated160,827,800 — 
Total200,000,000 25,572,200 
Dividends Declared
The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows:
Three Months Ended March 31,
20232022
SeriesPer ShareAggregatePer ShareAggregate
(In millions, except per share data)
A$0.361 $$0.250 $
D$29.375 15 $29.375 15 
E$351.563 11 $351.563 11 
F$296.875 12 $296.875 12 
G$19.250 19 $19.250 19 
Total$66 $63 
Class of Treasury Stock
MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows:
Authorization Remaining at
Announcement DateAuthorization AmountMarch 31, 2023
(In millions)
May 4, 2022$3,000 $425 
Components of Accumulated Other Comprehensive Income (Loss) Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows:
Three Months
Ended
March 31, 2023
Unrealized
Investment Gains
(Losses), Net of
Related Offsets
Unrealized
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)
Balance, beginning of period$(22,646)$1,557 $6,115 $107 $(6,377)$(1,377)$(22,621)
OCI before reclassifications7,583 387 (4,369)100 282 (4)3,979 
Deferred income tax benefit (expense)(1,728)(97)1,002 (21)(24)(867)
AOCI before reclassifications, net of income tax(16,791)1,847 2,748 186 (6,119)(1,380)(19,509)
Amounts reclassified from AOCI566 (132)— — — 30 464 
Deferred income tax benefit (expense)(129)33 — — — (6)(102)
Amounts reclassified from AOCI, net of income tax 437 (99)— — — 24 362 
Balance, end of period$(16,354)$1,748 $2,748 $186 $(6,119)$(1,356)$(19,147)
Three Months
Ended
March 31, 2022
Unrealized
Investment Gains
(Losses), Net of
Related Offsets
Unrealized
Gains (Losses)
on Derivatives
Future Policy Benefits Discount Rate Remeasurement Gains (Losses)Market Risk Benefits Instrument-Specific Credit Risk Remeasurement Gains (Losses)Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)
Balance, beginning of period$20,919 $1,629 $(18,559)$279 $(5,121)$(1,598)$(2,451)
OCI before reclassifications(21,450)(312)11,869 (107)(394)(10,391)
Deferred income tax benefit (expense)4,934 55 (2,611)23 (20)(1)2,380 
AOCI before reclassifications, net of income tax4,403 1,372 (9,301)195 (5,535)(1,596)(10,462)
Amounts reclassified from AOCI321 112 — — — 24 457 
Deferred income tax benefit (expense)(75)(20)— — — (3)(98)
Amounts reclassified from AOCI, net of income tax246 92 — — — 21 359 
Sale of subsidiary, net of income tax(30)— 53 — 38 (2)59 
Balance, end of period$4,619 $1,464 $(9,248)$195 $(5,497)$(1,577)$(10,044)
For information on offsets to investments related to policyholder liabilities, see “— Net Unrealized Investment Gains (Losses).”
Reclassification out of Accumulated Other Comprehensive Income (Loss)
Information regarding amounts reclassified out of each component of AOCI was as follows:
Three Months
Ended
March 31,
20232022
AOCI ComponentsAmounts Reclassified from AOCIConsolidated Statements of
Operations and
Comprehensive Income (Loss)
Locations
(In millions)
Net unrealized investment gains (losses):
Net unrealized investment gains (losses)
$(611)$(350)Net investment gains (losses)
Net unrealized investment gains (losses)
Net investment income
Net unrealized investment gains (losses)
43 27 Net derivative gains (losses)
Net unrealized investment gains (losses), before income tax
(566)(321)
Income tax (expense) benefit
129 75 
Net unrealized investment gains (losses), net of income tax
(437)(246)
Unrealized gains (losses) on derivatives - cash flow hedges:
Interest rate derivatives
14 15 Net investment income
Interest rate derivatives
18 Net investment gains (losses)
Interest rate derivatives
— Other expenses
Foreign currency exchange rate derivatives
Net investment income
Foreign currency exchange rate derivatives
111 (148)Net investment gains (losses)
Foreign currency exchange rate derivatives— Other expenses
Gains (losses) on cash flow hedges, before income tax
132 (112)
Income tax (expense) benefit
(33)20 
Gains (losses) on cash flow hedges, net of income tax
99 (92)
Defined benefit plans adjustment: (1)
Amortization of net actuarial gains (losses)
(33)(27)
Amortization of prior service (costs) credit
Amortization of defined benefit plan items, before income tax
(30)(24)
Income tax (expense) benefit
Amortization of defined benefit plan items, net of income tax
(24)(21)
Total reclassifications, net of income tax
$(362)$(359)
__________________
(1)These AOCI components are included in the computation of net periodic benefit costs. See Note 15.
Unrealized Gain (Loss) on Investments
The components of net unrealized investment gains (losses), included in AOCI, were as follows:
March 31, 2023December 31, 2022
(In millions)
Fixed maturity securities AFS
$(21,083)$(29,262)
Derivatives
2,231 1,976 
Other
543 549 
Subtotal
(18,309)(26,737)
Amounts allocated from:
Policyholder liabilities79 120 
Deferred income tax benefit (expense)
3,624 5,545 
Net unrealized investment gains (losses)
(14,606)(21,072)
Net unrealized investment gains (losses) attributable to noncontrolling interests
— (17)
Net unrealized investment gains (losses) attributable to MetLife, Inc.
$(14,606)$(21,089)